Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell’s new innovative therapy Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information.
Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, with three manufacturing/distribution facilities located in the U.S. Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream.
Rockwell’s exclusive renal drug therapies support disease management initiatives to improve quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing costs and improving patient convenience.
Rockwell’s new innovative therapy Triferic is the only FDA approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. Via dialysate during each dialysis treatment, Triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. Unlike IV iron products, Triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming Functional Iron Deficiency (FID) in ESRD patients. Visit www.triferic.com to view the Triferic mode-of-action (MOA) video and for more information.
Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, with three manufacturing/distribution facilities located in the U.S. Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream.
Rockwell’s exclusive renal drug therapies support disease management initiatives to improve quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing costs and improving patient convenience.
Location: United States, Michigan, Wixom
Employees: 201-500
Phone: +1 248-960-0772
Total raised: $15M
Founded date: 1995
Investors 1
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.06.2022 | - | $15M | - |
Mentions in press and media 7
| Date | Title | Description |
| 19.09.2025 | 5 takeaways from CNBC’s investigation into Walmart Marketplace | Walmart’s marketplace is a key part of its strategy to grow profit faster than sales and compete with Amazon, but a CNBC investigation uncovered new details about the risks the retailer is taking. CNBC found dozens of third-party sellers wh... |
| 16.11.2021 | Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update | - Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for i... |
| 31.03.2021 | ROCKWELL MEDICAL, INC. Rockwell Medical, Inc. Provides Fourth Quarter and Full Year 2020 Financial and Operational Update | - 2020 revenue of $62.2 million - - Ended the year with $58.7 million in cash, cash equivalents and investments - - Conference call and webcast on Wednesday, March 31st at 4:30 p.m. ET - WIXOM, Mich., March 31, 2021 (GLOBE NEWSWIRE) -- Rock... |
| 26.06.2013 | Rockwell Medical Snags $20M in New Financing | Share Share on Facebook Share on Twitter LinkedIn Email Reprints In May, we wrote about the Wixom, MI-based company Rockwell Medical, which disrupted the dialysis industry by being the first to develop, patent, and bring to market a dry aci... |
| 09.05.2013 | Rockwell Medical Set to Disrupt Dialysis Treatment With New Drugs, DaVita Deal | Share Share on Facebook Share on Twitter LinkedIn Email Reprints In the late 1990s, Wixom, MI-based Rockwell Medical revolutionized the dialysis industry by being the first to develop, patent, and bring to market a dry acid mixing system fo... |
| 26.02.2010 | Rockwell Medical’s anemia drug fails to meet efficacy goal in trial, shares plummet | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermin... |
| - | Rockwell Medical’s anemia drug fails to meet efficacy goal in trial, shares plummet | Rockwell Medical Technologies Inc. saw its stock lose about a quarter of its value in early trading Friday, after the company announced its iron deficiency anemia drug failed to meet its efficacy goal in a clinical trial. A Phase 2b study o... |